How do you start a compounding pharmacy business in 2027?

Two tiers, two entirely different businesses

Most people asking how to start a compounding pharmacy business think they are asking one question. They are actually asking two, and the answer to each is so different that treating them as variations of a single plan is the most expensive mistake a founder makes in year one.

The split traces to the Drug Quality and Security Act, passed in November 2013 in the aftermath of the New England Compounding Center disaster. NECC, a Massachusetts compounder, shipped contaminated methylprednisolone acetate injections in 2012 that caused a fungal meningitis outbreak — 64 deaths, roughly 750 people sickened across some twenty states, more than $200 million in civil settlements, and a criminal conviction for the company's president, Barry Cadden. Congress responded by writing two distinct legal categories into the Federal Food, Drug, and Cosmetic Act.

Section 503A describes what most people picture: a pharmacy compounding a specific medication for a specific patient against a valid prescription. The state Board of Pharmacy is the primary regulator. FDA is a backstop, not an inspector on a schedule. You must comply with USP General Chapters <795> for non-sterile work, <797> for sterile work, and <800> for hazardous drugs. Your bulk drug substances have to come from an FDA-approved drug product, carry a USP-NF monograph, or appear on the FDA's 503A bulks list. You cannot "essentially copy" a commercially available drug. And crucially, you are capped at shipping 5% of your total prescriptions out of state unless your state has signed a memorandum of understanding with the FDA — with an MoU, that ceiling rises substantially.

Section 503B describes an outsourcing facility: batch production of sterile injectables and other preparations, sold to hospitals, ambulatory surgery centers, and provider offices without a patient-specific prescription in hand. Registration with FDA is voluntary in name only — it is the price of admission to that market. Once registered, you fall under current Good Manufacturing Practice requirements in 21 CFR Parts 210 and 211, you get inspected by FDA on a biennial risk-based cycle, you report adverse events through MedWatch, and you file product reports twice a year. There is no interstate cap. There is also no forgiveness: a Form 483 observation or a warning letter becomes a public document that your hospital customers' procurement teams will read.

The practical translation for a founder: 503A is a small business with a professional license attached. 503B is a pharmaceutical manufacturing company that happens to be called a pharmacy. A 503A can be opened by an experienced compounding pharmacist with an SBA loan, a good lease, and eight to fourteen months of patience. A 503B is a capital project requiring private-equity or strategic backing, a quality assurance organization, a validated cleanroom, and eighteen to thirty-six months from groundbreaking to first commercial batch.

There is a third path people underweight: acquiring an existing compounding pharmacy. You buy the state license history, the prescriber relationships, the trained technicians, and — this is the real asset — a facility that has already passed inspection. Single-unit 503A pharmacies typically trade at roughly 2.5x–4.5x seller's discretionary earnings. For a founder whose scarce resource is prescriber trust rather than capital, buying is often faster and cheaper than building, because the eighteen months you spend detailing physicians from a standing start is the single largest hidden cost of a greenfield launch.

What the neighboring pharmacy formats teach you

It is worth being precise about what a compounding pharmacy is *not*, because the adjacent formats have wildly different economics and founders routinely import the wrong assumptions.

Retail and chain pharmacy — Walgreens, CVS, Walmart, Kroger, and the independents — dispenses manufactured product. Gross margins on brand drugs are thin, often in the low single digits after PBM reimbursement, and the business is really a front-of-store retail operation with a prescription counter attached. The independent retail owner lives and dies by generic acquisition cost and DIR fees. Nothing about that skill set prepares you for validating a cleanroom.

Mail-order and PBM-owned pharmacy — Express Scripts Home Delivery, CVS Caremark Mail, OptumRx Mail — is a logistics and adjudication business at enormous scale. Specialty pharmacy — Accredo, CVS Specialty, Walgreens' specialty arm, Diplomat before its acquisition — dispenses high-cost limited-distribution drugs under REMS programs, and its moat is manufacturer network access, not preparation skill.

Hospital inpatient pharmacy is the closest cousin to sterile compounding and the most useful training ground. A hospital pharmacist who has run IV admixture under USP <797>, managed environmental monitoring, and handled hazardous drugs under <800> already understands three-quarters of what a sterile 503A requires. That background is arguably the strongest predictor of a smooth licensure and inspection process.

Compounding's distinguishing economic feature is that it largely escapes the PBM. Because 65%–85% of compounded prescriptions are paid out of pocket, you set your own price against your own cost of goods. That produces gross margins in the roughly 48%–62% band for a mature 503A — numbers a retail pharmacy owner would find implausible. The trade is that you have no automatic demand. A retail pharmacy inherits foot traffic and insurance-driven refills. A compounding pharmacy has demand only to the degree that prescribers choose to write to you, which is why the whole business, from a RevOps perspective, is a prescriber-account book rather than a consumer-traffic book. Twenty-five well-cultivated prescribers can carry an entire location; the loss of three can wipe out a quarter.

How to decide which tier and which specialty

The decision is sequential, not simultaneous. Tier first, because it determines your capital requirement by an order of magnitude. Specialty second, because it determines your equipment, your prescriber targets, and your demand stability.

A few decision rules that matter more than they appear.

Do not add sterile capability in year one unless a named prescriber account requires it. The USP <797> cleanroom is the single largest line item in a 503A build, and it carries permanent operating cost: environmental monitoring, media fills, gowning supplies, personnel competency testing, sterility and endotoxin testing on batches. Founders routinely build sterile capacity "for optionality" and then spend three years amortizing a room they use twice a week.

Do not build the business on a single molecule. The 2023–2024 GLP-1 window is the cautionary tale of the decade. When semaglutide and tirzepatide were on the FDA drug shortage list, 503A pharmacies could legally compound them, and a telehealth-plus-compounding industry appeared almost overnight at $200–$450 a month against branded pricing many times that. FDA declared the semaglutide shortage resolved in October 2024 and tirzepatide in March 2025. The legal basis evaporated. Telehealth operators that had built their entire revenue line on compounded GLP-1s restructured or exited within months, and manufacturers pursued litigation against compounders and marketers. Any 2027 business plan whose base case depends on a shortage-list molecule is a plan with a regulatory expiration date printed on it.

Match the specialty to the prescriber relationships you actually have. This sounds obvious and is ignored constantly. A pharmacist with fifteen years of relationships with age-management and functional-medicine clinics should build a bioidentical hormone practice. A pharmacist whose network is veterinary should build flavored chewables and transdermals. The specialty that looks most attractive in a market report is rarely the one you can fill with prescriptions in month four.

The concrete numbers behind each path

Here is where the two paths diverge into different financial universes.

503A non-sterile, focused (BHRT or pain or dermatology). Space of roughly 1,500–2,500 square feet, often in a medical office building within five to ten miles of your prescriber base, at something like $22–$48 per square foot NNN in secondary markets and considerably more in Tier-1 metros. Expect a five-to-seven-year initial term with options, because your build-out is a fixed asset you cannot move. Landlord tenant-improvement allowances in the $30K–$80K range are common; larger in an MOB where the anchor wants a pharmacy.

Equipment for non-sterile work: a Class A analytical balance, NIST-traceable and calibrated on a schedule, in the $4K–$15K range; an electronic prescription balance at $1K–$4K; capsule machines from a few hundred dollars to a few thousand depending on capacity; a three-roll ointment mill at roughly $3K–$12K; suppository molds; hot plates and stirrers; monitored refrigeration at $3K–$8K. Add a pharmacy management system — PioneerRx is the compounding-aware option most independents cite, in the neighborhood of $700–$1,400 monthly, with BestRx, Liberty, ComputerRx, QS/1 NRx, and PrimeRx as alternatives. Add a formulary relationship: PCCA membership runs roughly $4K–$10K annually and brings a formula database in the ten-thousand-plus range, API supply, and education; Medisca, Letco, Spectrum, and Fagron are the alternatives.

All in: $250K–$600K, targeting $400K–$1.5M of revenue by year two or three.

503A with sterile capability. Add the cleanroom. An ISO Class 5 primary engineering control — a laminar airflow workbench at $8K–$22K, a biological safety cabinet at $15K–$45K, or a compounding aseptic isolator at $40K–$120K — sits inside an ISO Class 7 buffer room with an ISO Class 8 anteroom. The room itself runs roughly $400–$900 per square foot with HEPA-filtered HVAC at 15–30 air changes per hour, a pressure cascade, epoxy flooring, flush ceilings, an interlocked airlock, and gowning. A 300–1,000 square foot cleanroom lands somewhere between $120K and $900K. Ongoing sterility, endotoxin, media-fill, and glove-tip testing is a recurring five-figure annual cost, and continuous environmental monitoring equipment adds $15K–$60K.

If hazardous drugs are in scope under USP <800> — roughly 250 NIOSH-listed drugs — you need containment in a negative-pressure room with twelve or more air changes per hour vented externally, not recirculated, plus spill kits, deactivation protocols, and employee medical surveillance. Budget $80K–$400K on top of the baseline sterile build.

All in: $500K–$1.5M, targeting $1.0M–$5.0M of revenue at maturity.

503B outsourcing facility. Industrial or flex-industrial space of 15,000–80,000 square feet, cGMP cleanroom build at roughly $400–$1,200 per square foot, autoclaves, depyrogenation ovens, water-for-injection systems, clean steam, 21 CFR Part 11-compliant systems, and a quality control laboratory. Facility alone runs $5M–$30M on a greenfield; equipment another $2M–$15M; the QC lab $1M–$5M. You will need private-equity or family-office equity in the $3M–$25M range alongside senior bank debt from a healthcare lending group. Revenue at maturity ranges from $15M to well past $200M, at gross margins of roughly 22%–44% and EBITDA in the 6%–16% band — thinner percentages than 503A, on much larger absolute numbers.

Per-prescription economics for a 503A. A compounded prescription typically prices between $40 and $320 depending on specialty. Cost of goods breaks down as roughly $5–$80 of active pharmaceutical ingredient, eight to twenty-five minutes of compounding labor at $4–$15, packaging at $1–$5, and allocated overhead at $8–$25 — total cost in the $18–$125 range against that price. Bioidentical hormone scripts tend to run $60–$220 with a one-to-three-month refill cycle. Pain topicals sit higher at $90–$320. Dermatology lands around $70–$240. Pediatric flavoring and dose adjustment is low-ticket at $35–$110 but produces exceptionally loyal prescriber relationships. Veterinary spans $30–$180. Sterile ophthalmic preparations are premium, roughly $80–$280, with intravitreal work higher still.

Labor. The pharmacist-in-charge is the license. Expect $130K–$210K base, frequently with an EBITDA bonus and sometimes a small equity vest over three to four years. Staff pharmacists run $110K–$155K. Certified pharmacy technicians run roughly $19–$32 an hour, with state-mandated pharmacist-to-technician ratios typically between 3:1 and 6:1. A single-PIC 503A handles something like 25–80 prescriptions a day; a mature two-pharmacist operation with four to six technicians can push past 200.

Volume ramp. Year one is 15–40 prescriptions a day and $300K–$1.0M of revenue at negative-to-slightly-positive EBITDA. Years two to three reach 40–90 a day, $900K–$2.5M, and 8%–18% EBITDA. A second location in years three to five brings combined revenue to $2.0M–$5.0M at 10%–20% with shared back-office. Three to seven locations puts you at $5M–$25M and 12%–22%.

Insurance. Professional liability for a compounder is materially more expensive than for a retail pharmacy — contamination and dosing-error exposure is the reason — and you will also carry product liability, general liability, and workers' compensation. Get quotes early; lenders will ask for the binder.

Licensure, build sequencing, and the order operations must happen in

The sequencing trips up more launches than the money does, because several approvals are mutually dependent and a few have hard lead times you cannot compress.

The state Board comes before the DEA, and the DEA will not register you without it. Your DEA Form 224 application requires an active state pharmacy license at the specific address. That means your facility must be built, inspected, and permitted before you can even start a DEA process that itself takes weeks to months. Founders who budget for "licensing" as one parallel workstream discover it is a chain with no shortcuts. If you are opening a 503B, the relevant DEA registration is Form 225 for manufacturers, not 224.

HVAC capacity is the make-or-break site variable, and you evaluate it before signing. A cleanroom needs substantial air changes per hour, HEPA filtration, dedicated make-up air, and cooling capacity that most retail and medical-office shells were never built to supply. Bring a mechanical engineer to the site walk. A building that looks perfect on paper and cannot support the air handling turns a $400K build into a $700K build, and you will find out after you have signed a seven-year lease.

Non-resident licensure is a permanent operating burden, not a one-time filing. Every state into which you ship prescriptions requires a non-resident pharmacy license — typically a few hundred to a couple thousand dollars annually per state, with biennial renewals, separate inspection requirements in some jurisdictions, and independent complaint exposure. A compounder shipping into forty states carries a five-figure annual licensing cost and a compliance calendar that needs an owner. Many states will accept an NABP Verified Pharmacy Program inspection in lieu of their own, which is the single best lever for reducing that burden. Note that as a 503A you are still bound by the 5% interstate cap absent an MoU — build the shipping footprint only if the math actually works under that ceiling.

Standard operating procedures are graded, not just filed. State Board inspectors and, for 503B, FDA investigators will read your master formulation records, batch records, ingredient lot tracking, beyond-use-date determinations, stability data references, personnel training documentation, and cleaning logs. This documentation is the actual product of a compliance program. Write it before the inspection, not for it. Design the record system so a batch can be reconstructed end to end — ingredient lot, compounder, verification, packaging, label, dispensing — because that reconstruction is exactly what an investigator will ask you to perform on a randomly selected prescription.

Controlled substances add a parallel compliance stack. Schedule II drugs require separate secure storage, Form 222 or CSOS electronic ordering, biennial inventory, suspicious-order monitoring, and Form 41 documentation for destruction. DEA inspects on registration and periodically thereafter, and complaint-driven inspections happen. Diversion by an employee is a business-ending event, so the internal controls — dual counts, perpetual inventory, camera coverage of the vault — are worth more than their cost.

Demand generation, billing, and the revenue operations that decide survival

This is the section founders skip and then wish they had not. The regulatory build gets you the right to operate. It does not get you prescriptions.

Compounding demand is a prescriber-account business. For a single 503A, the overwhelming majority of revenue traces to something like five to twenty-five prescriber accounts. That concentration is the whole RevOps design problem: it means your growth motion looks far more like B2B field sales than retail pharmacy, and it means account concentration risk is your dominant business risk. Treat prescribers as named accounts with owners, coverage cadence, and pipeline stages, because that is what they are.

Detailing is the primary channel. A pharmacist-in-charge or a dedicated representative visiting eight to twenty-five prescriber offices a week, with a formulary catalog, prescription pads pre-printed with your common formulations, clinical literature, and periodic lunch-and-learns, remains the highest-yield acquisition motion in this industry. Budget roughly $40K–$120K annually for one representative plus materials. Track which prescriptions trace back to which visit — the attribution is straightforward here in a way it rarely is in consumer marketing, and it tells you which accounts deserve more coverage.

Clinic partnerships change the shape of the business. A preferred-pharmacy relationship with a hormone or functional-medicine clinic can move hundreds of prescriptions a month through a single relationship. That is extraordinary leverage and extraordinary fragility in the same arrangement. If one clinic is 40% of your volume, you do not have a pharmacy; you have a subcontract that can be terminated. The discipline is to pursue those relationships aggressively while capping any single account's share of revenue — a rule most operators learn the hard way.

Veterinary is the underrated adjacent market. It runs on inside sales rather than in-person detailing, competition is thinner, per-prescription revenue is lower, and loyalty is markedly higher. Veterinarians face genuine formulation problems — a cat that will not take a pill needs a transdermal, an exotic needs a dose that does not exist commercially — and a compounder who solves those reliably keeps the account for years.

Billing is where launches die. Because most large PBMs — Express Scripts, CVS Caremark, OptumRx, and others — exclude the majority of compound NDCs from their formularies, and because Medicare Part D rarely covers compounded preparations while Medicaid varies by state, you should model the business as cash-pay and treat any insurance reimbursement as upside. When a payer does cover, you are billing under a universal compound NDC with ingredient-level detail, prior authorization, and clinical justification, often at reimbursement below your cost and on a sixty-to-one-hundred-eighty-day cycle. Workers' compensation and some government programs are more reliable for specific indications and are worth pursuing selectively.

Cash-pay operations means you need real consumer payment infrastructure: card processing, HSA and FSA acceptance, and financing options for higher-ticket prescriptions. It also means price transparency is a competitive weapon — publish your pricing where prescribers can see it, because the physician's real question is whether their patient can afford the therapy they are about to recommend.

Retention is cheaper than acquisition, and refill cadence is knowable. Hormone therapy runs on a one-to-three-month cycle. Chronic pain topicals refill monthly. Build the reminder cadence — text and email at thirty, sixty, and ninety days — into the pharmacy management system from day one. A compounding pharmacy that lets a bioidentical hormone patient lapse silently is losing a multi-year annuity over a message that costs nothing to send.

Diversify deliberately. The lesson of the 2023–2025 GLP-1 cycle is not "avoid growth categories." It is that regulatory demand can vanish faster than you can rebuild a prescriber base. A pharmacy carrying hormone, pain, dermatology, pediatric, and veterinary lines simultaneously survives the loss of any one of them. A pharmacy that let four of those atrophy while chasing one lucrative molecule does not.

Related questions

Do I have to be a pharmacist to own a compounding pharmacy?

In many states, no — ownership can be held by non-pharmacists — but a licensed pharmacist-in-charge must be appointed and is legally accountable for the facility. Several states do restrict ownership. Check your specific state Board of Pharmacy statute before forming the entity.

Can I start with non-sterile compounding and add sterile later?

Yes, and it is usually the smarter sequence. Non-sterile under USP <795> requires far less capital and a much shorter path to licensure. Adding a USP <797> cleanroom later means a facility modification, re-inspection, and updated permit — but you will fund it from operating cash rather than debt.

How long before a new compounding pharmacy is profitable?

Most 503A pharmacies reach positive EBITDA somewhere in year two, once daily prescription volume clears roughly 40 per day. Plan for six to nine months of working capital beyond opening. Pharmacies that open with prescriber commitments already in hand get there considerably faster.

What happens if the FDA inspects my 503A pharmacy?

FDA can and does inspect 503A pharmacies, particularly on complaints or adverse-event reports. Observations are issued on Form 483. Your defense is documentation — master formulation records, batch records, environmental monitoring data, and personnel competency files that reconstruct any prescription end to end.

Is buying an existing compounding pharmacy better than starting one?

Often, yes. You acquire an inspected facility, an existing prescriber book, trained technicians, and immediate revenue, typically at 2.5x–4.5x seller's discretionary earnings. The risk is inheriting compliance debt, so commission a thorough regulatory and quality-systems review during diligence.

FAQ

What is the difference between a 503A and a 503B compounding pharmacy?

A 503A pharmacy prepares patient-specific medications against an individual prescription under state Board of Pharmacy oversight, with a 5% interstate shipping cap absent a state-FDA memorandum of understanding. A 503B outsourcing facility produces batches without patient-specific prescriptions, registers with FDA, operates under cGMP, ships nationally with proper state licenses, and undergoes biennial FDA inspection.

Do I need a DEA registration to start a compounding pharmacy?

Yes, if you will handle any controlled substances. A 503A registers using DEA Form 224 as a retail pharmacy; a 503B registers as a manufacturer using Form 225. Both require an active state license at the specific address first, plus compliance with DEA security, ordering, inventory, and recordkeeping requirements for Schedules II through V.

What USP standards apply in 2027?

USP <795> governs non-sterile compounding, USP <797> governs sterile compounding and its ISO-classified engineering controls, and USP <800> governs handling of hazardous drugs. The <795> and <797> revisions became official in November 2023 and <800> in December 2019, so facility design, air handling, beyond-use dating, and personnel training must all reflect the current chapters.

How long does it take to open?

Twelve to twenty-four months is realistic for a 503A from planning to first prescription, driven by facility construction, state Board licensure, and the DEA registration that can only begin once the state license is issued. A 503B greenfield runs eighteen to thirty-six months. Zoning approvals and inspection scheduling are the most common sources of delay.

Why is so much of compounding cash-pay?

Major pharmacy benefit managers exclude most compound preparations from their formularies, Medicare Part D rarely covers them, and Medicaid coverage varies by state. The result is that roughly two-thirds to five-sixths of compounded prescriptions are paid out of pocket — which is why compounding sustains gross margins retail pharmacy cannot, and why cash-pay operations are a core competency rather than an afterthought.

Should I compound GLP-1 medications in 2027?

Not as the foundation of a business. Legal compounding of semaglutide and tirzepatide depended on their presence on the FDA drug shortage list, and FDA declared those shortages resolved in October 2024 and March 2025 respectively. Manufacturer litigation and regulatory enforcement followed. Any shortage-dependent product line should be modeled as temporary revenue, never as the base case.

Sources

1. FDA — Human Drug Compounding: https://www.fda.gov/drugs/human-drug-compounding
2. FDA — Drug Quality and Security Act (DQSA): https://www.fda.gov/drugs/human-drug-compounding/drug-quality-and-security-act-dqsa
3. FDA — Registered Outsourcing Facilities: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
4. FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/
5. USP — General Chapter <795> Non-Sterile Preparations: https://www.usp.org/compounding/general-chapter-795
6. USP — General Chapter <797> Sterile Preparations: https://www.usp.org/compounding/general-chapter-797
7. USP — General Chapter <800> Hazardous Drugs: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare
8. National Association of Boards of Pharmacy: https://nabp.pharmacy
9. Alliance for Pharmacy Compounding: https://www.a4pc.org
10. U.S. Drug Enforcement Administration — Diversion Control Division: https://www.deadiversion.usdoj.gov

Related on PULSE

• [How Many Sales Reps Do I Need to Hire for My Specialty Pharmacy?](/knowledge/q15959)
• [How Do I Get My Pharmacy Staff to Drive Immunizations and Paid Services?](/knowledge/q15826)
• [How Many Staff Should I Schedule Each Day at My Pharmacy?](/knowledge/q15584)
• [How Do I Negotiate a Lease and Buildout for a Pharmacy?](/knowledge/q13752)
• [How Do I Get My Pharmacy Staff to Drive Front-of-Store Sales?](/knowledge/q15707)